BET inhibitors as novel therapeutic agents in breast cancer

Tumoral cells not only depend on oncogenic abnormalities to maintain its malignant phenotype but on non-oncogenic vulnerabilities. Targeting epigenomics can modify specific cellular functions required for malignant transformation. The Bromodomain (BRD) family mediates their effect by recruiting prot...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2017-09, Vol.8 (41), p.71285-71291
Main Authors: Ocaña, Alberto, Nieto-Jiménez, Cristina, Pandiella, Atanasio
Format: Article
Language:English
Subjects:
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c356t-cc4c5f2f23e9ad4eee78d63c12d16c9c73ff80fa64c4c2275d91b39d21219e2e3
cites cdi_FETCH-LOGICAL-c356t-cc4c5f2f23e9ad4eee78d63c12d16c9c73ff80fa64c4c2275d91b39d21219e2e3
container_end_page 71291
container_issue 41
container_start_page 71285
container_title Oncotarget
container_volume 8
creator Ocaña, Alberto
Nieto-Jiménez, Cristina
Pandiella, Atanasio
description Tumoral cells not only depend on oncogenic abnormalities to maintain its malignant phenotype but on non-oncogenic vulnerabilities. Targeting epigenomics can modify specific cellular functions required for malignant transformation. The Bromodomain (BRD) family mediates their effect by recruiting proteins of the transcription machinery, recognizing acetylated-lysine residues in nucleosomal histones. Bromodomain and extra-terminal (BET) inhibitors have shown to produce growth inhibition in several tumors through the inhibition of the expression of several transcription factors. In this review we will discuss the current knowledge regarding BET inhibitors in breast cancer. Recent data demonstrates their antiproliferative effect in several cancer subtypes, including the triple negative subtype, or when combined with cell signaling inhibitors. We will also describe options for therapeutic combinations or potential mechanisms of resistance, with special emphasis on their future clinical development.
doi_str_mv 10.18632/oncotarget.19744
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5642636</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1954065854</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-cc4c5f2f23e9ad4eee78d63c12d16c9c73ff80fa64c4c2275d91b39d21219e2e3</originalsourceid><addsrcrecordid>eNpVkE1Lw0AQhhdRbKn9AV4kRy-p2c9kEQQt9QMKXup52Wwm7Uqarbubgv_e0NZa5zID88w7Ly9C1zib4EJQcuda46L2S4gTLHPGztAQSyZTwjk9P5kHaBzCZ9YXZ3lB5CUaEJnxjAo8RPdPs0Vi25UtbXQ-JDokrdtCk8QVeL2BLlqT6CW0MfRYUnrQISZGtwb8FbqodRNgfOgj9PE8W0xf0_n7y9v0cZ4aykVMjWGG16QmFKSuGADkRSWowaTCwkiT07ousloL1oOE5LySuKSyIphgCQToCD3sdTdduYbK9Ga8btTG27X238ppq_5vWrtSS7dVXDAiqOgFbg8C3n11EKJa22CgaXQLrgsKS84ywQvOehTvUeNdCB7q4xucqV3u6i93tcu9v7k59Xe8-E2Z_gCkI4Jk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1954065854</pqid></control><display><type>article</type><title>BET inhibitors as novel therapeutic agents in breast cancer</title><source>PubMed Central</source><creator>Ocaña, Alberto ; Nieto-Jiménez, Cristina ; Pandiella, Atanasio</creator><creatorcontrib>Ocaña, Alberto ; Nieto-Jiménez, Cristina ; Pandiella, Atanasio</creatorcontrib><description>Tumoral cells not only depend on oncogenic abnormalities to maintain its malignant phenotype but on non-oncogenic vulnerabilities. Targeting epigenomics can modify specific cellular functions required for malignant transformation. The Bromodomain (BRD) family mediates their effect by recruiting proteins of the transcription machinery, recognizing acetylated-lysine residues in nucleosomal histones. Bromodomain and extra-terminal (BET) inhibitors have shown to produce growth inhibition in several tumors through the inhibition of the expression of several transcription factors. In this review we will discuss the current knowledge regarding BET inhibitors in breast cancer. Recent data demonstrates their antiproliferative effect in several cancer subtypes, including the triple negative subtype, or when combined with cell signaling inhibitors. We will also describe options for therapeutic combinations or potential mechanisms of resistance, with special emphasis on their future clinical development.</description><identifier>ISSN: 1949-2553</identifier><identifier>EISSN: 1949-2553</identifier><identifier>DOI: 10.18632/oncotarget.19744</identifier><identifier>PMID: 29050361</identifier><language>eng</language><publisher>United States: Impact Journals LLC</publisher><subject>Review</subject><ispartof>Oncotarget, 2017-09, Vol.8 (41), p.71285-71291</ispartof><rights>Copyright: © 2017 Ocaña et al. 2017</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-cc4c5f2f23e9ad4eee78d63c12d16c9c73ff80fa64c4c2275d91b39d21219e2e3</citedby><cites>FETCH-LOGICAL-c356t-cc4c5f2f23e9ad4eee78d63c12d16c9c73ff80fa64c4c2275d91b39d21219e2e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642636/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642636/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29050361$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ocaña, Alberto</creatorcontrib><creatorcontrib>Nieto-Jiménez, Cristina</creatorcontrib><creatorcontrib>Pandiella, Atanasio</creatorcontrib><title>BET inhibitors as novel therapeutic agents in breast cancer</title><title>Oncotarget</title><addtitle>Oncotarget</addtitle><description>Tumoral cells not only depend on oncogenic abnormalities to maintain its malignant phenotype but on non-oncogenic vulnerabilities. Targeting epigenomics can modify specific cellular functions required for malignant transformation. The Bromodomain (BRD) family mediates their effect by recruiting proteins of the transcription machinery, recognizing acetylated-lysine residues in nucleosomal histones. Bromodomain and extra-terminal (BET) inhibitors have shown to produce growth inhibition in several tumors through the inhibition of the expression of several transcription factors. In this review we will discuss the current knowledge regarding BET inhibitors in breast cancer. Recent data demonstrates their antiproliferative effect in several cancer subtypes, including the triple negative subtype, or when combined with cell signaling inhibitors. We will also describe options for therapeutic combinations or potential mechanisms of resistance, with special emphasis on their future clinical development.</description><subject>Review</subject><issn>1949-2553</issn><issn>1949-2553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpVkE1Lw0AQhhdRbKn9AV4kRy-p2c9kEQQt9QMKXup52Wwm7Uqarbubgv_e0NZa5zID88w7Ly9C1zib4EJQcuda46L2S4gTLHPGztAQSyZTwjk9P5kHaBzCZ9YXZ3lB5CUaEJnxjAo8RPdPs0Vi25UtbXQ-JDokrdtCk8QVeL2BLlqT6CW0MfRYUnrQISZGtwb8FbqodRNgfOgj9PE8W0xf0_n7y9v0cZ4aykVMjWGG16QmFKSuGADkRSWowaTCwkiT07ousloL1oOE5LySuKSyIphgCQToCD3sdTdduYbK9Ga8btTG27X238ppq_5vWrtSS7dVXDAiqOgFbg8C3n11EKJa22CgaXQLrgsKS84ywQvOehTvUeNdCB7q4xucqV3u6i93tcu9v7k59Xe8-E2Z_gCkI4Jk</recordid><startdate>20170919</startdate><enddate>20170919</enddate><creator>Ocaña, Alberto</creator><creator>Nieto-Jiménez, Cristina</creator><creator>Pandiella, Atanasio</creator><general>Impact Journals LLC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170919</creationdate><title>BET inhibitors as novel therapeutic agents in breast cancer</title><author>Ocaña, Alberto ; Nieto-Jiménez, Cristina ; Pandiella, Atanasio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-cc4c5f2f23e9ad4eee78d63c12d16c9c73ff80fa64c4c2275d91b39d21219e2e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Review</topic><toplevel>online_resources</toplevel><creatorcontrib>Ocaña, Alberto</creatorcontrib><creatorcontrib>Nieto-Jiménez, Cristina</creatorcontrib><creatorcontrib>Pandiella, Atanasio</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncotarget</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ocaña, Alberto</au><au>Nieto-Jiménez, Cristina</au><au>Pandiella, Atanasio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BET inhibitors as novel therapeutic agents in breast cancer</atitle><jtitle>Oncotarget</jtitle><addtitle>Oncotarget</addtitle><date>2017-09-19</date><risdate>2017</risdate><volume>8</volume><issue>41</issue><spage>71285</spage><epage>71291</epage><pages>71285-71291</pages><issn>1949-2553</issn><eissn>1949-2553</eissn><abstract>Tumoral cells not only depend on oncogenic abnormalities to maintain its malignant phenotype but on non-oncogenic vulnerabilities. Targeting epigenomics can modify specific cellular functions required for malignant transformation. The Bromodomain (BRD) family mediates their effect by recruiting proteins of the transcription machinery, recognizing acetylated-lysine residues in nucleosomal histones. Bromodomain and extra-terminal (BET) inhibitors have shown to produce growth inhibition in several tumors through the inhibition of the expression of several transcription factors. In this review we will discuss the current knowledge regarding BET inhibitors in breast cancer. Recent data demonstrates their antiproliferative effect in several cancer subtypes, including the triple negative subtype, or when combined with cell signaling inhibitors. We will also describe options for therapeutic combinations or potential mechanisms of resistance, with special emphasis on their future clinical development.</abstract><cop>United States</cop><pub>Impact Journals LLC</pub><pmid>29050361</pmid><doi>10.18632/oncotarget.19744</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1949-2553
ispartof Oncotarget, 2017-09, Vol.8 (41), p.71285-71291
issn 1949-2553
1949-2553
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5642636
source PubMed Central
subjects Review
title BET inhibitors as novel therapeutic agents in breast cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T11%3A23%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BET%20inhibitors%20as%20novel%20therapeutic%20agents%20in%20breast%20cancer&rft.jtitle=Oncotarget&rft.au=Oca%C3%B1a,%20Alberto&rft.date=2017-09-19&rft.volume=8&rft.issue=41&rft.spage=71285&rft.epage=71291&rft.pages=71285-71291&rft.issn=1949-2553&rft.eissn=1949-2553&rft_id=info:doi/10.18632/oncotarget.19744&rft_dat=%3Cproquest_pubme%3E1954065854%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c356t-cc4c5f2f23e9ad4eee78d63c12d16c9c73ff80fa64c4c2275d91b39d21219e2e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1954065854&rft_id=info:pmid/29050361&rfr_iscdi=true